Wednesday, February 04, 2026 7:35:34 PM
One thing I think gets lost in all the day-to-day noise is how far the company has actually come since
Sarissa Capital Management stepped in.
Before Sarissa, Amarin was drifting:
• bloated cost structure
• unclear strategy
• reactive instead of proactive
Since Sarissa took control, the shift has been obvious:
• expenses cut aggressively and rationally
• company re-oriented around cash flow discipline
• Europe stabilized instead of being abandoned
• legal strategy tightened and focused
• optionality preserved rather than forced
That kind of turnaround work doesn't show up immediately in the share price, and that doesn't mean it isn't happening. It just means the work is foundational, not cosmetic.Another tell that gets overlooked: Torok staying on board and going quiet. If the plan were bad, misaligned, or value-destructive, you would've heard noise. You didn't. That usually means alignment, not apathy.
Also worth saying out loud: if Alex Denner wanted a short-term pop in the stock, he could probably manufacture one. He has the relationships, the credibility, and the capital ecosystem to do that. The fact that he hasn't tells you something important - this is not about juicing the tape.
Sarissa isn't here to create a headline. They're here to create durable value, even if it takes time and even if the stock price doesn't immediately cooperate.So I don't read the lack of immediate share-price movement as failure. I read it as:• groundwork being laid
• leverage being preserved
• options being kept open
When this eventually resolves - legally and strategically - the market will reprice it all at once, not gradually.That's usually how these turnarounds work.
Sarissa Capital Management stepped in.
Before Sarissa, Amarin was drifting:
• bloated cost structure
• unclear strategy
• reactive instead of proactive
Since Sarissa took control, the shift has been obvious:
• expenses cut aggressively and rationally
• company re-oriented around cash flow discipline
• Europe stabilized instead of being abandoned
• legal strategy tightened and focused
• optionality preserved rather than forced
That kind of turnaround work doesn't show up immediately in the share price, and that doesn't mean it isn't happening. It just means the work is foundational, not cosmetic.Another tell that gets overlooked: Torok staying on board and going quiet. If the plan were bad, misaligned, or value-destructive, you would've heard noise. You didn't. That usually means alignment, not apathy.
Also worth saying out loud: if Alex Denner wanted a short-term pop in the stock, he could probably manufacture one. He has the relationships, the credibility, and the capital ecosystem to do that. The fact that he hasn't tells you something important - this is not about juicing the tape.
Sarissa isn't here to create a headline. They're here to create durable value, even if it takes time and even if the stock price doesn't immediately cooperate.So I don't read the lack of immediate share-price movement as failure. I read it as:• groundwork being laid
• leverage being preserved
• options being kept open
When this eventually resolves - legally and strategically - the market will reprice it all at once, not gradually.That's usually how these turnarounds work.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
